GlassScriptPhysician profile
Scott A Tetreault
NPI 1457334914
$15,202.94
in general payments reported to CMS, 2019-2025
82 companies · $1,524 in 2025
The $1,524 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,458 · 2020: $1,969 · 2021: $2,490 · 2022: $2,460 · 2023: $2,303 · 2024: $1,998 · 2025: $1,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,820 · Education: $6.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,819.68 |
| Education | $6.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,732.98 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Celgene Corporation | $1,124.88 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Astrazeneca Pharmaceuticals LP | $943.50 | 2019-2025 | Enhertu, Imfinzi, Tagrisso |
| Merck Sharp & Dohme LLC | $928.38 | 2019-2024 | Keytruda, Welireg, Lynparza |
| Amgen INC. | $863.84 | 2019-2023 | Kyprolis, Blincyto, Lumakras |
| Novartis Pharmaceuticals Corporation | $564.98 | 2019-2025 | |
| Genzyme Corporation | $508.51 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $479.68 | 2019-2025 | Onivyde, Somatuline Depot |
| Seagen INC. | $449.44 | 2019-2023 | Adcetris, Tukysa |
| Gilead Sciences, INC. | $446.08 | 2021-2025 | Trodelvy |
| Daiichi Sankyo INC. | $389.70 | 2019-2025 | Enhertu |
| Genentech USA, INC. | $366.93 | 2019-2025 | Polivy, Venclexta, Tecentriq |
| Abbvie INC. | $347.10 | 2019-2025 | Venclexta |
| Glaxosmithkline, LLC. | $327.78 | 2020-2025 | Ojjaara, Shingrix |
| Eisai INC. | $320.72 | 2019-2025 |
Show all 82 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Tetreault listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.